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in Renal Disease equation. All patients with baseline CKD or solitary kidney were excluded prior
to the matching analysis. The complication was noted with modified Clavien grades  3. Statis-
tical analysis was performed to compare the perioperative incidence of complications and CKD.
Results: A total of 27 matched pairs of RFA and RALPN patients were enrolled for analyzing CKD
and perioperative complications. The better general conditions, higher estimated blood loss andhave no conflicts of interest to declare.
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Propensity-matched comparison between RALPN and RFA 127transfusion rates, and longer operative time and hospital stay were observed significantly in
RALPN patients (p < 0.05). Matched analysis demonstrated that the incidences of both periop-
erative complications (p Z 0.434) and of CKD (p Z 0.500) were not significantly different. No
complication higher than Grade 4 was detected in either group.
Conclusion: Despite the intraoperative renal ischemia and invasiveness of the procedure associ-
ated with RALPN, the incidence of perioperative complication and of CKD developing rates were
statistically similar.
Copyright ª 2014, Asian Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In the past number of decades, radical nephrectomy (RN)
was still considered the gold standard for the treatment of
renal cell carcinoma (RCC). However, many patients
deemed unsuitable for RN owing to their underlying pre-
operative conditions such as solitary kidney, renal insuffi-
ciency, and high-risk comorbidities underwent other
minimally invasive nephron-sparing procedures such as
ablative therapy or partial nephrectomy (PN).
Many reports showed that PN yielded not only compa-
rable 5- and 10-year survival rates to RN, but also better
clinical outcomes especially in patients with high-risk
comorbidities or with selected RCCs for preserving the
postoperative renal function.1,2 To reduce the procedural
complications, and to spare renal function and prevent
chronic kidney disease (CKD), radiofrequency ablation
(RFA) therapy has demonstrated comparable clinical and
oncologic outcomes in select patients with small RCCs
during short- and long-term follow-ups.3,4 Robot-assisted
laparoscopic partial nephrectomy (RALPN) also showed
similar surgical and renal preserving outcomes to the open
surgery.5
No study as yet has evaluated RALPN compared to RFA
using comparable patient groups equally matched in terms
of age, sex, tumor location, tumor laterality, and clinical T
stage. This study presented a propensity-matched pair
analysis of RALPN and RFA performed by a heterogeneous
group of surgeons and radiologists in two hospitals to
compare the incidences of perioperative (peri-) complica-
tions and of CKD between RALPN and RFA as a nephron-
sparing procedure.
2. Materials and methods
The Institutional Review Boards of the participating in-
stitutions (Seoul National University Hospital, Seoul, Korea;
Seoul National University Bundang Hospital, Seoul, Korea,
B 1202/145-102) approved the retrospective review of the
medical records of patients with a single renal mass without
LN invasion nor metastasis managed by either RFA or RALPN
decided under the surgeons’ and patients’ preferences and
patients’ general performance states between June 2005 to
December 2011.
The overall inclusion criteria for RFA and RALPN included
patients aged over 19 years, a newly developed solid renal
mass smaller than approximately 4 cm with RCCconfirmation via computerized tomography scan or mag-
netic resonance images, and with a normal contralateral
kidney. The specific inclusion criteria for RFA were patients:
(1) who refused the recommended surgery (otherwise con-
ventional surgery was first chosen for the treatment) and
had small tumors that were easy to access using RFA, (2)
who were unable to undergo surgery because of underlying
diseases, and (3) in whom renal function preservation was
paramount. The exclusion criteria included any advanced
states of RCC whether it indicated positive lymph nodes or
metastasis, and any patients with baseline serum creatinine
level > 1.4 ng/dL or solitary kidney or calculated an esti-
mated glomerular filtration rate (eGFR) < 60 mL/minute/
1.72 m2, which was calculated according to the Modification
of Diet in Renal Disease (MDRD) formula:
MDRD-eGFR Z 186.3  Pcr1.154  age0.203  0.742 (1)
(if female) by considering serum creatinine, sex, and
age. A total of 60 RFAs were performed in 41 patients and
206 RALPNs were performed in 203 patients. All RALPNs and
RFAs were performed by a heterogeneous group of six
experienced surgeons in PN and two experienced radiolo-
gists in ablation therapy.
The RFA was impedance-based and performed percuta-
neously using a single probe, under ultrasonic (US) and
fluoroscopic guidance. A 17-gauge internally cooled tip
radiofrequency (RF) electrode (Cool-tip; Radionics, Burling-
ton, MA, USA) with a 3-cm tip was placed near the targeted
tumor under US guidance. The electrode tip location was
verified with different projections to ensure the juxtaposi-
tioning of the tip and the renal pelvis without perforation.
RF energy was applied at the maximal allowable output
(140 W) for 12 minutes per tumor, at a target temperature of
105C. The applied current, power output, and impedance
were continuously monitored during RF ablation, and these
parameters were recorded automatically using Real Time
Graphics Software version 2.0 (Radionics).
Patients were matched for age, sex, tumor size, clinical
T stage, tumor location, and renal laterality, using optimal
matching based on propensity scores (Fig. 1). Matching the
propensity scores of the smallest absolute distance across
all matched pairs was used to compare individually pairwise
matching between RFA and RALPN, and the bigger RALPN
group was used as a control.6,7 A follow-up protocol after
RALPN and RFA was performed according to a consistent
protocol with postoperative follow-up of the European
Association of Urology guidelines in all patients including
Figure 1 Box-plot of propensity scores between RFA and RALPN groups. This plot describes the demographics of RFA and RALPN
groups after they were matched based on propensity scores. RALPN Z robot-assisted laparoscopic partial nephrectomy;
RFA Z radiofrequency ablation.
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were made prior to the surgery and at 4e6 weeks,
3 months, 6 months, and 12 months post-surgery, semi-
annually until the 5th year, and annually thereafter.8
To evaluate the incidence rate of developing perioper-
ative complications and CKD, different matching pairs of
enrollment were used. The matching variables of tumor
location and kidney laterality were divided into endo-
phytic, exophytic, mesophytic, and hilar categories, and
into right and left. All renal tumor images were classified
according to the RENAL nephrometry score, which consists
of the following parameters: R (radius), E (exophytic/
endophytic), N (nearness), A (anterior/posterior), and
L (location), as described previously.9 The clinical T stage
was used according to the classification of the International
Union Against Cancer/American Joint Committee on Can-
cer, 2009. Other clinicopathologic data and related vari-
ables to CKD and perioperative complications were
evaluated between the two groups.
The primary clinical outcomes were perioperative com-
plications, and renal function. Perioperative complications
were graded using the modified Clavien classification,10
which was validated for PN11 and ablation therapy.12 A
perioperative complication was defined as any major
complication classified as Clavien grade  3 after either
RFA or RALPN within 1 month. Functional outcome wasbased on an eGFR-MDRD, and CKD is defined as eGFR <
60 mL/minute/1.73 m2.
Group differences in continuous and categorical data
were compared using the independent t test or Wilcoxon
signed rank sum test, and chi-square or Fisher’s exact tests,
respectively. Intrapersonal changes in eGFR were assessed
using paired t tests. The propensity score was calculated
with an SAS macro after modeling logistic regression and
McNemar test, and using the penalized maximum likelihood
ratio to compare between the two groups. All analyses
were performed with the SAS statistical software (SAS sys-
tem for Windows, version 9.2; SAS institute, Cary, NC, USA).
A p value < 0.05 was considered statistically significant.
3. Results
During a median follow-up of 14.6 months, 27 paired cases
of RFA and of RALPN were matched to evaluate the inci-
dence of complications and the renal function for devel-
oping postoperative incidence of CKD. Among the 54 cases,
two RALPN patients and two RFA patients dieddthree from
cancer-related and one from noncancer-related causesdat
a median follow-up of 6.5 months after the treatment. For
patients with RALPN, hilar vessel clamping was performed
in all cases with a mean warm ischemic time of 20.4
(standard deviation  6.9) minutes (Table 1).
Table 1 Comparison for CKD and postoperative complications between RALPN and RFA.
Variables RALPN (n Z 27) RFA (n Z 27) p
Age (y) 60.33  15.61 58.67  11.60 0.627 a
Sex (male/female) 19 (70.4)/8 (29.6) 22 (81.5)/5 (18.5) 0.549 b
Body mass index (kg/m2) 25.9  3.4 26.6  3.1 0.127
Diabetes 4 (14.8) 5 (18.5) > 0.99 c
Hypertension 16 (59.3) 11 (40.7) 0.101 c
ASA score 1.0  0.2 1.6  0.5 < 0.001
1 26 14
2 1 13
Follow-up duration (mo) 10.9  7.0 16.7  10.5 0.068
Preop. Cr (mg/dL) 0.9  0.2 1.2  0.2 < 0.001
Preop. Hb (mg/dL) 14.2  1.2 13.0  1.7 0.003
Preop. eGFR (mL/min/1.73 m2) 86.7  14.1 84.0  23.5 0.049
Tumor size 1.77  0.96 1.8  0.81 0.928 a
Laterality 0.267 b
1: left 16 (59.3) 11 (40.7)
2: right 11 (40.7) 16 (29.3)
Location 0.462 b
1: exophytic 13 (50.0) 13 (50.0)
2: mesophytic 4 (15.3) 2 (7.7)
3: endophytic 8 (30.8) 8 (30.8)
4: hilar 1 (3.9) 3 (11.5)
RENAL score (sum) 6.5  1.7 6.3  1.6 0.748
R 1.1  0.2 1.1  0.3 0.973
E 2.1  0.8 2.0  0.7 0.671
N 1.8  0.9 1.8  1.0 0.832
A 0.5  0.5 0.8  0.4 0.086
L 1.6  0.7 1.4  0.7 0.591
Tumor distance to collecting system or sinus (mm) 9.0  6.3 7.5  6.8 0.462
Clinical T stage 0.513 b
T1 22 (81.5) 23 (85.2)
T2 0 0
T3 5 (18.5) 4 (14.8)
Total operative time (min) 167.9  66.0 NA NA
Warm ischemic time (min) 20.4  6.9 NA NA
Safety margin (mm) 3.9  3.1 NA NA
Estimated blood loss (mL) 162.0  119.2 NA NA
Transfusion 1 (3.7) 0 > 0.99 c
Histology 27 (100) 5 (18.5) < 0.003 c
Clear cell 19 (70.1) 2 (5.4)
Papillary 4 (14.8) 1 (3.7)
Chromophobe 1 (3.7) 0
Angiomyolipoma 1 (3.7) 0
Oncocytoma 2 (5.4) 2 (5.4)
Hospital stay (d) 6.2  1.5 3.0  2.2 < 0.001
Postop. Hb (mg/dl) 13.3  1.3 12.5  1.5 0.084
Postop. eGFR (mL/min/1.73 m2) 80.5  16.5 81.3  27.8 0.303
Postop. Cr change (mg/dl) 0.02  0.21 0.03  0.41 0.912
eGFR change (mL/min/1.73 m2) d 6.2  2.4 2.8  0.7 0.049
Postop. CKD 1 (3.7) 3 (11.1) 0.500 b
Complication 3 (11.1) 4 (14.8) 0.434 e
Pyelo/pyonephritis 0 1 (3.7)
Hydronephrosis 0 1 (3.7)
Wound 1 (3.7) 0
Bleeding 2 (7.4) 0
Urine leak 0 2 (7.4)
Tumor recurrence 2 (7.4) 1 (3.7) 0.669
(continued on next page)
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Table 1 (continued )
Variables RALPN (n Z 27) RFA (n Z 27) p
Death 0.764
Cancer-related cause 2 (7.4) 1 (3.7)
Noncancer-related cause 0 1 (3.7)
Data are presented as n (%) or mean  SD.
ASA Z American Society of Anesthesiologists score; CKD Z chronic kidney disease; Cr Z creatinine; GFR Z glomerular filtration rate
(MDRD); NA Z not available; Preop. Z preoperative; Postop. Z postoperative; RALPN Z robot-assisted laparoscopic partial ne-
phrectomy; RFA Z radiofrequency ablation.
a Paired t test.
b McNemar test.
c Fisher’s exact test.
d eGFR change is the estimated glomerular filtration change between before and after operation or procedure.
e Conditional logistic regression analysis.
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parameters between RALPN and RFA, univariate analysis
revealed that baseline general performance states with
serum creatinine, hemoglobin, eGFR, and American Soci-
ety of Anesthesiologists score were significantly better in
RALPN and that post-eGFR change and hospital stay were
significantly lower and shorter in RFA (p < 0.05, Table 1).
Other operative parameters of RALPN were noncompa-
rable to those of RFA with greater mean estimated blood
loss (162.0  119.4 mL), longer operative time
(167.9  66.0 minutes), and higher transfusion rate
(3.7%). Biopsy prior to RFA was performed in only 18
(66.6%) cases, and five (18.5%) cases confirmed the cell
histology.
Among the 27 RFA matched patients, CKD developed in
three patients (11.1%) with a mean eGFR change from 84.0
( 23.5) mL/minute/1.73 m2 to 81.3 ( 27.8) mL/minute/
1.73 m2 after 6 months, representing a mean eGFR differ-
ence of 2.8 ( 0.7) mL/minute/1.73 m2. For 27 RALPN pa-
tients, CKD developed in one patient (3.7%), and the mean
eGFR decreased from 86.7 ( 14.1) mL/minute/1.73 m2 to
80.5 ( 16.5) mL/minute/1.73 m2, with a mean eGFR dif-
ference of 6.2 ( 2.4) mL/minute/1.73 m2. Propensity-
matched analysis demonstrated that the incidences of
CKD were not significantly different between RFA and
RALPN (p Z 0.500; Table 2).Table 2 Comparative results of perioperative incidence




Non-CKD 26 (96.3) 24 (92.6) 50 0.500 a




24 (88.9) 23 (85.2) 47 0.434 a
With
complication
3 (11.1) 4 (14.8) 7
Data are presented as n (%).
CKD Z chronic kidney disease; RALPN Z robot-assisted lapa-
roscopic partial nephrectomy; RFA Z radiofrequency ablation.
a McNemar test.For perioperative complications, no major complication
of Grade 4 was detected in either group; however, four
(14.8%) patients developed complications in RFA and three
(11.1%) patients did so in RALPN, in which the incidences of
major complications of Grade  3 were not significantly
different in the matched analysis (pZ 0.434; Table 2). The
complications in RFA consisted of two urinary leaks neces-
sitating the intervential insertion of percutaneous
drainage, one flank pain with moderate hydronephrosis that
resolved after the insertion of a ureteral stent, and one
severe pyonephritis managed by RN after the failure of
medical management. According to the modified Clavien
classification, there were three Grade 3a (8.0%) and one
Grade 3b (2.6%) complications. For complications in the
RALPN group, there was one infected wound problem that
resolved after surgical therapy (3.7%, Grade 3a), and two
prolonged bleeding cases necessitating two transfusions
with radiologic intervential embolizations for pseudoa-
neurysm (7.4%, Grade 3a).4. Discussion
During the past few decades, open PN was considered the
established treatment for RCCs < 4 cm in size with com-
parable clinico-oncologic outcomes to RN and with better
preservation of the renal function, thus preventing post-
operative CKD.1,2 Many studies reported that RALPN was
superior to open PN in terms of intraoperative blood loss
and length of hospital stay. Its renal functional change was
proven to be not different from that of PN.5,13
As the advanced diagnostic imaging techniques had led
to a marked diagnostic increase of small renal masses with
no evidence of metastasis in patients with multiple
comorbidities or with a solitary kidney, the rate of PN might
increase the risk of surgery for these patients. These facts
helped to introduce alternative thermal ablation tech-
niques such as RFA, which are reserved for carefully
selected high-surgical-risk patients with renal masses
smaller than approximately 4 cm, reportedly without
compromising the oncologic outcomes to PN (like the re-
sults of this study), in that the similar tumor recurrence and
insignificant difference of cancer-related death rates
happened all in patients with Stage 3a RCC (Table 1).4,14
And the reasons behind the better preservation of renal
function in RFA compared with PN were attributable to
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reperfusion injuries, invasive surgical resection or electro-
cauterization of the renal parenchyma as well as tumors,
and increased intraoperative bleeding loss in PN.15 These
speculations on the reduction of postoperative renal func-
tion being greater than that observed in RFA were also
easily applied to RAPLN. However, no comparison of RALPN
and RFA has been carried out, and no reports have been
presented on this topic to date. Therefore, this study marks
the first effort to compare the renal function and the
incidence of developing CKD, as well as perioperative
complication(s) between RALPN and RFA. To compare these
two procedures, it was important to consider the charac-
teristics of tumors as well as the patients’ demographic
data so that the two study populations would be evenly
matched in terms of age, sex, tumor size, clinical T stage,
and its renal laterality and locations within the kidney.
This study demonstrated that RFA and RALPN matched
patients had almost no serious postoperative reductions in
eGFR that would be sufficient to cause postoperative CKD.
Therefore, the incidence of CKD after the treatment was
not statistically different between the two groups (RFA
3/27 vs. RALPN 1/27, pZ 0.500). This finding was similar to
that in other reports, wherein the difference in CKD inci-
dence was observed between PN and thermal ablation.3,16
As regards the predisposing characteristics of four pa-
tients who developed CKD after the treatment, they were
younger than 65 (range 36e65) years and all were staged
T1a (tumor size range 0.9e2 cm), they had the same sex
ratio (2 males and 2 females), and they had good Eastern
Cooperative Oncology Group status (2 Grade 0, and 2 Grade
1 with diabetes (DM) and hypertension (HTN)). Their renal
tumors were located more in the left side than in the right
side (3:1), and two were endophytic tumors and the other
two were exophytic tumors. Their eGFRs were between
60.7 mL/minute/1.73 m2 and 89.4 mL/minute/1.73 m2
prior to the treatment, and between 55.0 mL/minute/
1.73 m2 and 59.3 ml/minute/1.73 m2 after the treatment.
All the predisposing factors of CKD including age, sex, un-
derlying diseases, and tumor locations and sizes showed no
significant findings owing to the limited number of CKD
patients in this study.
Other interesting findings were observed in changes of
eGFR. First, in spite of the insignificant differences in
terms of developing CKD, the change differences of eGFR
between baseline and after treatment were significant
after 6 months, and the decrease of eGFR in RALPN was
greater than that in RFA [6.2  2.4 mL/minute/1.73 m2
(RALPN) vs. 2.8  0.7 (RFA) mL/minute/1.73 m2,
p Z 0.049]. This meant that RFA resulted in less kidney
functional deterioration compared with RALPN. This result
might be explained by previously suggested explan-
ationsdischemic injury during the clamping procedure,
cauterizing injury, and resected volume of renal paren-
chyma in PN. In this study, the warm ischemic time in
RALPN was 20.4  6.9 minutes, which was less than a
reportedly tolerable time of 28 minutes for renal ischemic
injury, so that the effect of ischemic injury might not be
negatively great on renal function. Nevertheless, our re-
sults showed a significant decrease of renal function after
RALPN compared with that after RFA in consideration of
post-eGFR change.Although this is the first comparison report dealing with
the renal function and perioperative complications of
RALPN and RFA, similar previous comparative studies be-
tween PN and thermal ablation have been reported, in
which RFA performed better in preserving renal function
and PN negatively affected renal function more than RFA
did in small RCCs.14,15,17 Another recent retrospective study
that compared RALPN and cryoablation in a large number of
patients during long-term follow-up showed that RALPN
offers significantly better renal preservation than cryoa-
blation.18 However, these studies did not match RCC pa-
tients for age, sex, or tumor size, location, laterality, and
stage. Without considering tumor size and location, com-
parisons of surgery and ablative therapy are difficult. Pre-
vious studies compared different and widely ranging tumor
sizes that were treated by surgery versus varied and
smaller-sized tumors treated with ablative therapy.17,18
Therefore, it was not surprising that their results are
different from ours.
A second interesting finding from our results was that
some improvement of eGFR after the operation or pro-
cedures was observed in both groups [RFA, 9/27 (33.3%);
RALPN 10/27 (37%); data not shown in tables]. The obser-
vation that eGFR did not decrease after the treatment was
speculative because the procedural insult to the small
treatment area was insufficient to cause renal function
deterioration after the procedure, and the remnant pa-
renchyma of the affected kidney and the contralateral
normal kidney were stimulated to compensate for
decreased renal function by expressing multiple media-
tors.19,20 Additionally, the local hypoxia-inducing effect of
tumor on the juxtaposed renal parenchyma disappeared
after tumor removal or ablation. The disappearance of
tumor inflammatory immune responses enabled renal
function to restore normoxia by erythrocytosis of RCC21 and
several inflammatory immune mediators.22
Another attendant objective in our study was the com-
parison of major complication rates between RFA and
RALPN, conclusively resulting in similar complication rates
and grades [RFA 4/27 (14.8%) vs. RALPN 3/27 (11.1%), 4 RFA
Grade 3a vs. 3 RALPN with 2 Grade 3a and 1 Grade 3b,
respectively; p > 0.05]. Our results were consistent with
other analyses that compared ablative therapy with PN, as
they also showed similar complication rates in both
groups.15,23 Some reports showed RALPN to be superior to
PN of small RCCs in terms of clinicopathological outcomes
including perioperative complications.5 However, our re-
sults on enrolled cases selected after matching important
baseline clinical parameters to propensity scores demon-
strated no statistical superiority of RALPN over RFA, but
similarity in perioperative complication.
For the relationship with complication(s) and multiple
treatments in the same patient, three RFA patients (11.1%)
had more than two procedural histories because of multiple
tumors. However, no perioperative complication occurred
in those RFA patients, although it had been reported that
multiple procedures correlated with the incidence of peri-
operative complication due to multiple ablations of normal
renal tissue including the tumor tissue.24,25
The complication rate of RFA in this study appeared
relatively high compared to that of other reports (incidence
9.3e11.0%, and grade 3, 4.3e6.6%),24,25 whereas the
132 S.H. Kim et al.incidence rate of RALPN complication with two bleeding
and one wound dehiscence was relatively similar to that in
previous reports (5e12%).5 One suggested explanation for
the high incidence rate of RFA complication was that the
RFA used in this study was performed percutaneously under
US and fluoroscopic guidance rather than under comput-
erized tomographic (CT) guidance, which was the option
used in other previous studies. CT-guided RFA is known to
yield better results, with higher accuracy in the treatment
of small renal tumors, thereby resulting in lower compli-
cation rates.26
Discussion of the high incidence rate and specific com-
plications after RFA was carried out in this study. Two uri-
nomas from urinary leakages occurred, necessitating
percutaneous drainage, and one urinary obstruction with
hydronephrosis owing to mild stricture in the collecting
system required insertion of a ureteral stent that resolved
completely after its removal after 2 weeks. Urinomas usu-
ally resolve with ureteral stenting, whereas strictures in the
collecting system may require further endopyelotomy or
reconstructive surgery after ureteral stenting.27 These
complications were well known complications in RFA
because of the locations of the tumors near the pelvoca-
lyceal system (or ureteropelvic junction), such that the
thermal injury with coagulation necrosis in the pelvocaly-
ceal system results in either urine leakage or stricture
formation causing hydronephrosis.28 One patient among the
three suggested patients had a tumor near the pelvocaly-
ceal system, but he was selected for RFA because he was
unable to undergo other surgeries requiring general anes-
thesia owing to an underlying comorbidity. For such cases,
although RFA has been used to treat small renal tumors of
any size and any location even in the central hilum and
renal sinus near the major vessels,29 considerable care
should be exercised when treating tumors especially those
lying in continuity with the collecting system of renal hilum
and major vessels, for which RFA is not highly
recommended.30
Another possibility of urine leakage in this study might
be related to the 17-gauge Cooltip probe used in our RFA
procedure. The 17G single probe Cooltip might leave a large
bore hole in the tumor, making leaks more likely compared
with the 25G tines used in the array-type probes. However,
to prevent urinary leakage from occurring after the RFA,
some form of preprocedural management such as ureteral
stenting might be helpful to avoid complications of the
urinary system in some high-risk patients. Therefore, it is
important to establish a close collaboration between the
urologist and the interventional radiologist in such high-risk
patients with small renal tumors.
The last complicated case in RFA was a patient with
pyonephritis who underwent nephrectomy, which was
related to infection of the affected kidney. The nephrec-
tomy case had multiple underlying comorbidities including
diabetes and steroid-induced immune suppression, as a
result of which pyelonephritis progressed to pyonephritis
despite the medical treatment. Pyelonephritis happened
because RFA produces thermal coagulation necrosis and
protein denaturation, which can result in inflammation of
the affected renal parenchyma.31
Our study has several limitations. This was a retrospec-
tive review of a relatively small group of patients withdifferent comorbidities and short-term follow-up. As the
follow-up time lengthens, the CKD prevalence might be
increasingly affected, because renal function deteriorated
over time and one of the most important predisposing
factors for CKD was age.1,3,4 Mukkamala et al32 recently
reported the postoperative time-related CKD prevalence in
their study. They noted that clinically significant CKD pro-
gressed in a small number of patients 5 years after the
treatment, but in almost one-half of their patients, it
occurred 10 years after the surgery. However, in this study,
the prevalence of CKD after 5 years might not be as high as,
or even similar to, what one might expect, because many
predisposing factors had already been matched. Second,
the highly specialized and experienced surgeons and radi-
ologists were composed of a heterogeneous group from two
tertiary teaching hospitals to render the skill differences
among the professional staff. Third, the evolution of RFA
technology over the study period might have resulted in the
overestimation of RFA complications and the underestima-
tion of RFA-associated CKD prevalence.5. Conclusion
Despite intraoperative renal ischemia and the invasiveness
of the procedures associated with RALPN, the perioperative
complications and CKD developing rates were statistically
similar in a propensity-matched control study. However,
the study shows that RFA had slightly better renal preser-
vation effects than RALPN in high-risk patients with small
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